CytoImage Dx

[On Demand]

Immunotherapy-Small Molecule Combination Functional Drug Response -
CytoImage Dx has developed a proprietary platform technology that provides multiplexed quantification of protein function in single cells with exceptionally sensitive evaluation of the drug response. CytoImage performs validated blood-based assays for functional drug sensitivity screening in ex vivo (pre-clinical) and in vitro (clinical) patient testing environments.
The future of cancer treatment will leverage the potential of combination therapy, driven by the advancements in Immuno-Oncology. The challenge is to find the right combinations of immunotherapy drug combinations and match them to the right patients.

CytoImage Dx is presenting as part of the NIH Innovation Zone.

Company Type:
Privately Funded Company
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Single Cell Protein Function Imaging - CytoScreen
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
CytoImage DX (paid by OTRADI)